GOSS
Closed
Gossamer Bio Inc
1.25
+0.02 (+1.63%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.23
Day's Range: 1.195 - 1.33
Send
sign up or login to leave a comment!
When Written:
1.175
Gossamer Bio Inc is a clinical-stage biopharmaceutical company that develops and commercializes immunology-based therapies to treat patients with life-threatening diseases. The company was founded in 2015 and is headquartered in San Diego, California.
Gossamer Bio's pipeline includes several drug candidates in various stages of development, targeting diseases such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). The company's lead product candidate, GB001, is an oral small molecule antagonist of prostaglandin D2 receptor 2 (DP2) that is being developed for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio has collaborations with several pharmaceutical companies, including Pfizer and Merck, to develop and commercialize its drug candidates. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol "GOSS."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Gossamer Bio's pipeline includes several drug candidates in various stages of development, targeting diseases such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). The company's lead product candidate, GB001, is an oral small molecule antagonist of prostaglandin D2 receptor 2 (DP2) that is being developed for the treatment of moderate-to-severe eosinophilic asthma.
Gossamer Bio has collaborations with several pharmaceutical companies, including Pfizer and Merck, to develop and commercialize its drug candidates. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol "GOSS."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








